Pfizer has signed an agreement with Israeli company, Protalix, to develop and commercialise Uplyso (taliglucerase alfa), a novel proprietary plant cell-based enzyme replacement therapy for treatment of Gaucher’s disease. It gives Pfizer entry into orphan drugs and access to a plant cell-based technology for the development of biosimilars.